BERLIN, June 22 (Reuters) - EQT's Galderma on
Wednesday said its injectable drug nemolizumab helped patients
suffering from the rare skin disease prurigo nodularis in a
trial, potentially underpinning the owner's ambitions to list
the skincare firm.
In a late-stage trial, Galderma's drug was shown to remove
lesions and ease itch in some patients. Itch is a chronic
symptom of the potentially debilitating skin disease.
Sources told Reuters in May that EQT is delaying listing
plans for Galderma as market volatility and recession fears in
Europe cool investor appetite for what could be Switzerland's
biggest flotation in more than two decades.
The listing could happen in the autumn or early next year
depending on market conditions, the sources said at the time.
Japan's Maruho Co. Ltd is also working on a prurigo
nodularis treatment while French drugmaker Sanofi is
running trials to get its bestselling eczema drug Dupixent also
approved for the disease.
(Reporting by Ludwig Burger, Writing by Miranda Murray)